• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Safety of Eptifibatide in Subarachnoid Hemorrhage Patients Requiring Antiplatelet Agents. (P2.285)
Conclusions:Our results indicate that administering IV Eptifibatide to prevent thrombotic complications after endovascular coil embolization in selected patients with aneurysmal subarachnoid hemorrhage is safe. Multicenter prospective trials are warranted to corroborate our findings.Disclosure: Dr. Mehta has nothing to disclose. Dr. Song has nothing to disclose. Dr. DeCarvalho has nothing to disclose. Dr. Z Arango has nothing to disclose. Dr. Kulhari has nothing to disclose. Dr. Kirmani has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Mehta, S., Song, Y.-B., DeCarvalho, B., Arango, A. Z., Kulhari, A., Kirmani, J. F. Tags: Subarachnoid Hemorrhage, Intracranial Aneurysm, and Other Cerebrovascular Malformations Source Type: research

Eptifibatide Is Safe and May Improve Outcomes in Stroke Patients Undergoing Thrombectomy after Receiving IVtPA (P2.276)
CONCLUSION: The addition of eptifibatide bolus followed by a continuous drip for a mean of 24-hours to IV tPA/thrombectomy was associated with a significantly better 24-hour post-procedure outcome and is safe. This could be due to suppression of inflammation and potential prevention of rethrombosis after treatment. A larger prospective trial is warranted to corroborate our findings.Disclosure: Dr. Mehta has nothing to disclose. Dr. Moussavi has nothing to disclose. Dr. Korya has nothing to disclose. Dr. Brar has nothing to disclose. Dr. Chahal has nothing to disclose. Dr. Kondapalli has nothing to disclose. Dr. Samaan has ...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Chahal, H., Mehta, S., Moussavi, M., Korya, D., Brar, J., Kondapalli, S., Samaan, M., Shaikh, A., Kalola, R., Song, Y.-B., Kirmani, J. Tags: Acute Therapy: Thrombolysis and Adjuvant Therapy Source Type: research

Is Eptifibatide a Viable and Safe Option as Stand-Alone Therapy for Acute Ischemic Stroke Patients? (P2.278)
Conclusion: In patients who are not candidates for IV tPA eptifibatide may be a safe and efficacious alternative. None of the patients who were started on eptifibatide had bleeding complications and they had a statistically significant improvement in their level of disability and stroke severity at discharge. To better evaluate the efficacy of eptifibatide, a larger, prospective study should be initiatedDisclosure: Dr. Korya has nothing to disclose. Dr. Moussavi has nothing to disclose. Dr. Mehta has nothing to disclose. Dr. Brar has nothing to disclose. Dr. Chahal has nothing to disclose. Dr. Daniel has nothing to disclos...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Mehta, S., Moussavi, M., Korya, D., Brar, J., Chahal, H., Daniel, J., Samaan, M., Panezai, S., Kirmani, J. Tags: Acute Therapy: Thrombolysis and Adjuvant Therapy Source Type: research

Phase I Experience of Safety of Eptifibatide in Select Patients with Elective Cerebral Aneurysm Embolization (P1.250)
Conclusion: IV Eptifibatide may represent another safe option for rapid and reversible antiplatelet therapy for reduction of thromboembolic complication associated with aneurysmal embolization in select patient population.Disclosure: Dr. Brar has nothing to disclose. Dr. Moussavi has nothing to disclose. Dr. Mehta has nothing to disclose. Dr. Korya has nothing to disclose. Dr. Chahal has nothing to disclose. Dr. Daniel has nothing to disclose. Dr. Samaan has nothing to disclose. Dr. Song has nothing to disclose. Dr. Hussain has nothing to disclose. Dr. Kirmani has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Daniel, J., Brar, J., Moussavi, M., Mehta, S., Korya, D., Chahal, H., Samaan, M., Song, Y.-B., Hussain, M., Kirmani, J. Tags: Aneurysms and Subarachnoid Hemorrhage Source Type: research

Novel Application of Reversible Parental Anti-platelets in Patients with Aneurysmal Subarachnoid Hemorrhage (P1.257)
CONCLUSION: Our results highlight safety of administering IV Eptifibatide to prevent thrombotic complications after endovascular coil embolization in select patients with aneurysmal subarachnoid hemorrhage. Multicenter prospective trials are warranted to corroborate our findingsDisclosure: Dr. Mehta has nothing to disclose. Dr. Moussavi has nothing to disclose. Dr. Korya has nothing to disclose. Dr. Brar has nothing to disclose. Dr. Chahal has nothing to disclose. Dr. Samaan has nothing to disclose. Dr. Daniel has nothing to disclose. Dr. Song has nothing to disclose. Dr. Kirmani has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Mehta, S., Moussavi, M., Korya, D., Brar, J., Chahal, H., Samaan, M., Daniel, J., Song, Y.-B., Kirmani, J. Tags: Aneurysms and Subarachnoid Hemorrhage Source Type: research

Loading doses of aspirin and clopidogrel prior to Enterprise stent-assisted repair of intracranial aneurysm-a pilot study (P3.117)
Conclusions: Loading dose of antiplatelet in Enterprise stent-assisted repair of intracranial aneurysm is not only safe and feasible but associated with good clinical outcome. Therefore, loading doses antiplatelets is an alternative option for patients who are candidates for stent-assisted repair of intracranial aneurysm.Disclosure: Dr. Lodi has nothing to disclose. Dr. Reddy has nothing to disclose. Dr. Devasenapathy has nothing to disclose. Dr. Shehadeh has nothing to disclose. Dr. Hourini has nothing to disclose. Dr. Chou has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Lodi, Y., Reddy, V., Devasenapathy, A., Shehadeh, K., Hourini, A., Chou, C.-A. Tags: Cerebrovascular Disease and Interventional Neurology: Subarachnoid Hemorrhage and Miscellany Source Type: research

Combination Therapy of Intravenous Glycoprotein IIB-IIIA Inhibitors and Tissue Plasminogen Activator for Acute Ischemic Stroke (P1.112)
Conclusion Combination of low dose IV tPA with GpIIb/IIIa inhibitor is associated with better functional outcome at 90 days as well as reduction in sICH rates in patients with acute ischemic stroke as compared to 0.9g/kg IVtPA.Disclosure: Dr. Sawhney has nothing to disclose. Dr. Dubey has nothing to disclose. Dr. Banerjee has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Sawhney, A., Dubey, D., Banerjee, C. Tags: Cerebrovascular Disease and Interventional Neurology: Antiplatelet Agents and Miscellaneous Source Type: research

Is Intracranial Intra-Arterial Thrombolysis and Thrombectomy Expertise Necessary for Carotid Artery Stent Procedures in Contemporary Practice? (P02.046)
CONCLUSIONS: Although neurological deterioration following CAS can be infrequently seen, the rate and value of intra-arterial thrombolysis and thrombectomy for cerebral ischemic events is very low.Disclosure: Dr. Hartmann has nothing to disclose. Dr. Chaudhry has nothing to disclose. Dr. Allam has nothing to disclose. Dr. Chaudhry has nothing to disclose. Dr. ATACH Investigators has nothing to disclose.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Hartmann, A., Chaudhry, S., Allam, H., Seeman, E., Qureshi, A. Tags: P02 Cerebrovascular Disease II Source Type: research